Dr. Plotkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St Yaw 9
Brain Tumor Center Neuro-Oncology
Boston, MA 02114Phone+1 617-724-8770Fax+1 617-724-8769
Education & Training
Massachusetts General HospitalFellowship, Neuro-Oncology, 2002 - 2003
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1999 - 2002
Tulane UniversityInternship, Internal Medicine, 1998 - 1999- Tulane University School of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2024 - 2026
MA State Medical License 2002 - 2025
NH State Medical License 2023 - 2025
LA State Medical License 2002 - 2002- American Board of Psychiatry and Neurology Neurology
- United council of neurological subspecialtiesNeuro-Oncology
Clinical Trials
- Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 Start of enrollment: 2008 Mar 01
- Concentration and Activity of Lapatinib in Vestibular Schwannomas Start of enrollment: 2009 Jun 01
- Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- 268 citationsImproved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T. Batchelor, Elizabeth R. Gerstner, Kyrre E. Emblem, Dan G. Duda, Jayashree Kalpathy-Cramer
Proceedings of the National Academy of Sciences of the United States of America. 2013-11-19 - 398 citationsPhase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent GlioblastomaTracy T. Batchelor, Dan G. Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Scott R. Plotkin
Journal of Clinical Oncology. 2010-06-10 - 368 citationsRandomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma MultiformeDavid A. Reardon, Karen Fink, Tom Mikkelsen, Timothy F. Cloughesy, Alison M. O'Neill
Journal of Clinical Oncology. 2008-12-01
Journal Articles
- Increasing Access to Specialty Care for Rare Diseases: A Case Study Using a Foundation Sponsored Clinic Network for Patients with Neurofibromatosis 1, Neurofibromatosi...Scott R Plotkin, Justin T Jordan, BioMed Central
Press Mentions
University of Miami Miller School of Medicine Selected for National NF2 Tumor Clinical TrialJune 1st, 2022
Wayne Biopharma Firm Targeting Rare Genetic Disorders Raises $6MMay 1st, 2020
Antiangiogenesis Treatment Improves Hearing in Some NF2 PatientsJuly 8th, 2009- Join now to see all
Grant Support
- Fetal Alcohol Effects On Blood Brain Barrier TransportNational Institute On Alcohol Abuse And Alcoholism1995–1997
- Fetal Alcohol Effects On Blood Brain Barrier TransportNational Institute On Alcohol Abuse And Alcoholism1994
Professional Memberships
- Member
Industry Relationships
- Co-Founder, NF2 Therapeutics
- Co-Founder, NFlection Therapeutics
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
